Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

PHASE3TerminatedINTERVENTIONAL
Enrollment

1,015

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Hypercholesterolemia
Interventions
DRUG

25 mg/day AVE5530

"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"

DRUG

50 mg/day AVE5530

"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"

DRUG

placebo

"* one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)"

Trial Locations (16)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

sanofi-aventis Australia & New Zealand administrative office, Macquarie Park

Sanofi-Aventis Administrative Office, Diegem

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Prague

Sanofi-Aventis Administrative Office, Hørsholm

Sanofi-Aventis Administrative Office, Paris

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Netanya

Sanofi-Aventis Administrative Office, Gouda

Sanofi-Aventis Administrative Office, Lysaker

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Moscow

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Bromma

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY